Search | Clinical Trials Finder

Conditions: Seasonal Allergic Rhinitis
Interventions: Ciclesonide HFA 160 μg, Ciclesonide HFA 80 μg, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 671 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 7
States / cities: Austin, Texas • New Braunfels, Texas • San Antonio, Texas

Conditions: Hay Fever, Perennial Allergic Rhinitis
Interventions: Ciclesonide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 2 Years to 5 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 3
States / cities: Long Beach, California • Normal, Illinois • San Antonio, Texas

Conditions: Acute Otitis Media, Allergic Rhinitis, Sinusitis, Constipation, Pharyngitis, Croup, Urticaria, Bronchiolitis
Interventions: Electronic point-of-care delivery system; Device
Lead sponsor: University of Washington; Other
Eligibility: 0 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2003
U.S. locations: 2
States / cities: Seattle, Washington • Skagit Valley, Washington

Conditions: Allergic Rhinitis, Seasonal Allergic Rhinitis
Interventions: Fluticasone propionate, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 626 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Allergic Rhinitis, Asthma, Back Pain, Benign Prostatic Hypertrophy, Bursitis, Depression, Anxiety, Diabetes Mellitus, Esophageal Reflux, HIV Infections, Hyperlipidemia, Hypertension, Insomnia, Irritable Bowel Syndrome, Obesity, Osteoporosis (Senile), Shoulder Pain, Sinusitis, Symptomatic Menopause, Urinary Incontinence, Urinary Tract Infection, Vaginitis
Interventions: Health Information Prescription; Other
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Seasonal Allergic Rhinitis
Interventions: levocetirizine dihydrochloride, placebo; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 580 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 38
States / cities: Tucson, Arizona • Los Angeles, California • Sacramento, California + 35 more

Conditions: Perennial Allergic Rhinitis With Seasonal Variation
Interventions: allergen immunotherapy; Other
Lead sponsor: United Allergy Services; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Seasonal Allergic Rhinitis
Interventions: Bepotastine besilate, Placebo; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Irvine, California

Conditions: Hay Fever, Seasonal Allergic Rhinitis
Interventions: Ciclesonide nasal spray; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 71
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Costa Mesa, California + 65 more

Conditions: Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
Interventions: Ciclesonide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 636 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 58
States / cities: Oxford, Alabama • Huntington Beach, California • Mission Viejo, California + 52 more

Conditions: Atopic Dermatitis, Eczema, Asthma, Food Allergies, Allergic Rhinitis
Interventions: Lipikar Balm AP; Drug
Lead sponsor: Cosmetique Active International; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Canton, Michigan • Fort Gratiot, Michigan

Conditions: Seasonal Allergic Rhinitis
Interventions: Vitamin D3, Placebo, Fluticasone Propionate; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 45 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Allergic Rhinitis
Interventions: Grass MATA MPL 10200, Grass MATA MPL 18200, Placebo; Biological
Lead sponsor: Allergy Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Neptune City, New Jersey • Newark, New Jersey

Conditions: Rhinitis, Allergic, Perennial
Interventions: FPNS, FFNS, placebo FFNS, placebo FPNS; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 20 more

Conditions: Allergic Rhinitis
Interventions: Nasaleze Spray, Placebo spray, Allergen; Drug · Other · Biological
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 45 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Allergic Rhinitis
Interventions: Fexofenadine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Allergies, Allergic Rhinitis, Asthma
Interventions: sublingual immunotherapy, placebo sublingual immunotherapy; Drug
Lead sponsor: Stanford University; Other
Eligibility: 5 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: Rhinitis, Allergic, Seasonal
Interventions: STAHIST NDC #58407-536-01; Drug
Lead sponsor: Magna Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Asthma, Allergic Rhinitis, Atopic Dermatitis
Interventions: Omalizumab, Placebo; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 55 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Allergic Rhinitis, Allergic Rhinitis Due to Grass Pollen, Healthy Volunteers
Interventions: B244 suspension, Vehicle; Biological
Lead sponsor: AOBiome LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Tustin, California

Conditions: Allergic Rhinitis
Interventions: placebo, isotonic ciclesonide, hypotonic ciclesonide; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Rhinitis, Allergic, Perennial
Interventions: fluticasone propionate (FP), fluticasone furoate (FF); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 14
States / cities: Fountain Valley, California • Long Beach, California • San Diego, California + 11 more

Conditions: Seasonal Allergic Rhinitis
Interventions: Bepotastine Besilate Nasal Spray 2% Twice a day, Bepotastine Besilate Nasal Spray 3% Twice a day, Bepotastine Besilate Nasal Spray 4% Twice a day, Placebo Nasal Spray; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Irvine, California

Conditions: Rhinitis, Allergic, Perennial
Interventions: Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol, Placebo Nasal Aerosol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 35
States / cities: Los Angeles, California • Mission Viejo, California • San Diego, California + 30 more

Search by objective public record fields.

Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older

Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)

A Trial of Point of Care Information in Ambulatory Pediatrics

Assessment of Fluticasone Propionate on Ocular Allergy Symptoms

Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow

A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis

The Efficacy & Safety of the UAS Immunotherapy Protocol

Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR)

Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)

Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)

Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis

Vitamin D Plus Fluticasone Propionate

A Study of Tolerability and Safety of Two New Doses of Grass MATA MPL

Comparator Study Evaluating Patient Experience And Preference Of FFNS vs. FPNS

Effect of Nasaleze on Nasal Challenge With Allergen

Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine

Sublingual Immunotherapy Studies for Grass and Dust Mite Allergies

Clinical Trial of STAHIST in Seasonal Allergic Rhinitis Patients

Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)

Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis

A Pilot Investigation of Ciclesonide When Administered as a Hypotonic Versus an Isotonic Formulation of Ciclesonide Nasal Spray

Fluticasone Nasal Spray Patient Preference Study

Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Seasonal Allergic Rhinitis

Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)